Servier shared on LinkedIn:
“EANS 2026 has come to an end!
We were delighted to connect with the European and international neurosurgical community, share perspectives, and discuss the challenges and opportunities ahead in neuroscience.
In line with our hashtag Servier 2030 strategy, we invest close to 70% of our R/D budget in oncology research, with a particular focus on cancers where significant unmet medical needs remain.
You can also read: Oncology Research and Therapeutic Innovations at EANS 2026 – Servier
